Great progress has been made in reducing cardiovascular mortality over the past 50 years. Nevertheless prevalence is rising in some setti...
Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
- Citation data:
Lancet (London, England), ISSN: 1474-547X, Vol: 390, Issue: 10095, Page: 709-711
- Publication Year:
- Most Recent Tweet View All Tweets
- Most Recent News Mention
Great progress has been made in reducing cardiovascular mortality over the past 50 years. Nevertheless, prevalence is rising in some settings and remains higher in men than in women, even with the same level of established risk factors. To gain new insights, researchers are now considering cardiovascular disease in relation to the well known evolutionary biology model of growth and reproduction trading off against longevity, with trials of calorie restriction underway. However, calorie restriction has not been as successful as expected in primates and it is increasingly realised that effects on the reproductive axis might also be important. In this paper, the modulation of the reproductive axis using existing agents that have such properties-tachykinin neurokinin 3 receptor antagonists-is proposed as a way of reducing cardiovascular disease and combating a leading cause of global morbidity and mortality.